

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited and ASX	
Name of listed issuer:	Metlifecare Limited
Date this disclosure made:	12 October 2017
Date of last disclosure:	12 October 2016

A. Director or senior manager giving disclosure

Full name(s):	Glen Robert Sowry
Name of listed issuer:	Metlifecare Limited
Name of related body corporate (if applicable):	N/A
Position held in listed issuer:	Chief Executive Officer

B. Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Owner (as a participant in Metlifecare Limited's senior executive restricted share plan)
For that relevant interest-	
Number held in class before acquisition or disposal:	31,045
Number held in class after acquisition or disposal:	64,277
Current registered holder(s):	N/A
Registered holder(s) once transfers are registered:	Metlifecare LTIP Trustee Limited

C. Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	N/A
Class of underlying financial products:	N/A
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
<i>For that derivative,-</i>	
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A


D. Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	12 October 2017
Nature of transaction:	Issue of shares further to Metlifecare Limited's senior executive restricted share plan
Name of any other party or parties to the transaction (if known):	Metlifecare Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	\$193,048.01
Number of financial products to which the transaction related:	33,232
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	
Whether relevant interests were acquired or disposed of during a closed period:	The ordinary shares were issued as part of Metlifecare Limited's senior executive restricted share plan, therefore, Metlifecare Limited's financial products trading policy did not apply to the allotment. In any case, the shares are not issued during a closed period
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A

E. Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
<i>For that relevant interest,-</i>	
Number held in class:	N/A
Current registered holder(s):	N/A
<i>For a derivative relevant interest,-</i>	
Type of derivative:	N/A
Details of derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price's specified terms (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A

F. Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	12 October 2017
Name and title of authorised person:	Andrew Peskett, General Counsel and Company Secretary